Resources

For the latest information about how to find HSCT clinical trials, be sure to visit ClinicalTrials.gov

Following are some resources highlighting the latest HSCT research.

We’re keeping an eye out for Dr. Richard Burt’s upcoming publication… for a preview and the most up-to-date information about HSCT, watch this presentation of Dr. Burt being honored with the esteemed Van Bekkum award at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in March 2018 held in Lisbon, Portugal.

More information about this latest study can be seen in Dr. Burt’s Day 1 and Day 3 presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation, March 2018 held in Lisbon, Portugal.

presentation by Dr. Burt at the Cellular Horizons: How Science, Technology, Information and Communication Will Impact Society conference in Vatican City, April 28-30, 2016, includes testimonial from two patients.

If you know of additional resources not on the list, please share a link or citation through the Contact page.

References

Atkins, H.L., Bowman, M., Allan, D., Anstee, G., Arnold, D.L., Bar-Or, A., Bence-Bruckler, I., Birch, P., Bredeson, C., Chen, J., Fergusson, D., Halenny, M., Hamelin, L., Huebsch, L., Hutton, B., Laneuville, P., Lapierre, Y., Lee, H., Martin, L., McDiarmid, S., O’Connor, P., Ramsay, T., Sabloff, M., Walker, L., Freedman, M.S., (2016). Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial. Lancet, 388(10044):576-85.

Bakhuraysah, M.M., Siatskas, C., & Petratos, S., (2016). Hematopoietic stem cell transplantation for multiple sclerosis: Is it a clinical reality? Stem cell research & therapy, 7(12). doi:10.1186/s13287-015-0272-1

Boster, A., Hreha, S., Berger, J.R., Bao, F., Penmesta, R., Tselis, A., Endress, C., Zak, I., Perumal, J. Caon, C., Vazquez, J., Tyler, K.L., Racke, M.K., Millis, S., & Khan, O., (2009). Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: A comparative study. Journal of the American Medical Association, Neurology, 66(5):593-599. doi:10.1001/archneurol.2009.31

Burman, J., Iacobaeus, E., Svenningson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A., Uggla, B., Lenhoff, S., Johansson, J., Isaksson, C., Hagglund, H., Carlson, K., & Fagius, J., (2014). Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: The Swedish experience. Journal of Neurological Neurosurgery Psychiatry, 2(25):1-6. doi:10.1136/ jnnp-2013-307207

Burt, R.K., Balabanov, R., Han, X., Sharrack, B., Morgan, A., Quigley, K., Yaung, K., Helenowski, I.B., Jovanovic, B., Spahovic, D., Arnautovic, I., Lee, D.C., Benefield, B.C., Futterer, S., Oliveira, M.C., & Burman, J., (2015). Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. Journal of the American Medical Association, 313(3):275-284. doi:10.1001/jama.2014.17986

Burt, R.K., Loh, Y., Cohen, B., Stefosky, D., Balabanov, R., Katsamakis, G., Oyama, Y., Russell, E.J., Stern, J., Muraro, P., Rose, J., Testori, A., Bucha, J., Jovanovic, B., Milanetti, F., Storek, J., Voltareli, J.C., & Burns, W.H., (2009). Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study. Lancet, 09(70017-1). doi:10.1016/S1474-4422

Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J, Ouyang J, Kozak T., Moore J., Kötter I., Chesnel V., Marmont, A., Gratwohl, A., & Saccardi, R., (2010). Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica, 95:284-292. doi:10.3324/haematol.2009.013458

Fassas, A., Kimiskidis, V.K., Sakellari, I., Kappinas, K., Anagnostopoulos, A., Tsimourtou, V., Sotirakoglou, K., Kazis, A., (2011). Long-term results of stem cell transplantation for MS: A single-center experiences. Neurology, 2011 Mar 22, 76(12): 1066-70. doi:10.1212/WNL.0b013e318211c537

Hartung, D.M., Bourdette, D.N., Ahmend, S.M., & Whitham, R.H., (2015). The cost of multiple sclerosis drugs in US and the pharmaceutical industry: Too big to fail? Neurology, 84:2185-92. doi:10.1212/WNL.0000000000001608

Krasulova, E., Trneny, M., Kozak, T., Vackova, B., Pohlreich, D., Kemlink, D., Kobylka, P., Kovarova, I., Lhotakova, P., & Havrdova, E., (2010). High-dose immunoablation with autologous hematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Multiple Sclerosis, 16(6): 685-693. doi:10.1177/1352458510364538

Kurtzke, J.F., (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11): 1444-1452.

Mancardi, G.L., Sormani, M.P., Vuolo, G.L., Gualandi, F., Amato, M.P., Capello, E., Curro, D., Uccelli, A., Bertolotto, A., Gasperini, C., Lugaresi, A., Merelli, E., Meucci, G., Mottie, L., Tola, M.R., Scarpini, E., Repice, A.M., Massacesi, L., Saccardi, R., (2011). Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience. Multiple Sclerosis Journal, 18(6): 835-842. doi:10.1177/1352458511429320

Nash, R.A., Hutton, G.J., Racke, M.K., Popat, U., Devine, S.M., Griffith, L.M., Muraro, P.A., Openshaw, H., Sayre, P.H., Stuve, O., Arnold, D.L., Spychala, M.E., McConville, K.C., Harris, K.M., Phippard, D., Georges, G.E., Wndes, A., Kraft, & Bowen, J.D., (2015). High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis: A 3-year interim report. Journal of the American Medical Association, Neurology, 72(2):159-169. doi:10.1001/jamaneurol.2014.3780

Rimel, B.J., (2016). Clinical trial accrual: Obstacles and opportunities. Frontiers in Oncology, 6:103. doi:10.3389/fonc.2016.00103

Rogne, S. (2017). Unethical for neurologists not to offer patients with multiple sclerosis chemotherapy with autologous stem cell support. Tidsskr Nor Legeforen, 20(17 January 2017):1931-2. doi:10.4045/tidsskr.14.1027

Saccardi, R., Freedman, M.S., Sormani, M.P., Atkins, H., Farge, D., Griffith, L.M., Kraft, G., Mancardi, G.L., Nash, R., Pasquini, M., Martin, R., Muraro, P.A., (2012). A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Multiple Sclerosis Journal, 18(6): 825-834. doi:10.1177/1352458512438454

Weinshenker, B.G., Bass, B., Rice, G.P., Noseworthy, J., Carriere, W., Baskerville, J., Ebers, G.C., (1989). The natural history of multiple sclerosis: A geographically based study. Brain, Feb.(112):133-146. doi:10.1093/brain/112.1.133

Facilities

Reputable hospitals/clinics that offer HSCT around the world include:

Northwestern Memorial Hospital
Dr. Richard Burt
Division of Immunotherapy and Autoimmune Diseases
Chicago, Illinois USA

Sheffield Teaching Hospitals NHS Foundation Trust
(modeled after Northwestern protocols)
Royal Hallamshire Hospital,
Sheffield, UK

Uppsala University
(modeled after Northwestern protocols)
Uppsala, Sweden

A.A. Maximov Department of Hematology and Cellular Therapy
Dr. Denis Fedorenko
Moscow, Russia

Ottawa General Hospital
Dr. Mark Freedman
Ottawa, Canada

Clinica Ruiz
Puebla, Mexico